EXHIBIT 99.1


[VIROLOGIC LOGO]

FOR IMMEDIATE RELEASE                                  Contact:
NOVEMBER 14, 2002                                      Karen Wilson, CFO
                                                       (650) 624-4164
                                                       kwilson@virologic.com


               VIROLOGIC ANNOUNCES $7.0 MILLION PRIVATE PLACEMENT


SOUTH SAN FRANCISCO, Calif., November 14, 2002 -- ViroLogic, Inc. (Nasdaq: VLGC)
today announced it has entered into an agreement to sell newly issued shares of
8% convertible preferred stock to a group of investors comprised of existing and
new stockholders.

The Company expects to raise $7 million from the private placement, which is
subject to closing conditions and expected to close by November 19, 2002. These
proceeds are in addition to a 5% equity investment in ViroLogic made by Pfizer
Inc., also announced today.*

ViroLogic expects to use the net proceeds from this financing to support and
enhance ongoing commercial activities and for general administrative expenses,
capital expenditures and working capital.

The preferred stock will be convertible into common stock at a premium to the
current market price.  The purchasers will also receive warrants to purchase a
total of 4.4 million shares of common stock, at an exercise price that is based
on the five day trading average. In connection with the closing of the private
placement, the Company's Series B Preferred Stock is expected to be exchanged
for short-term convertible debt which, subject to the approval of our
stockholders, would automatically convert into the new preferred stock.

*  Pfizer's ownership percentage is calculated on an as-converted to common
stock basis, assuming conversion of all the outstanding preferred stock.

ABOUT VIROLOGIC

ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious viral diseases such as AIDS and hepatitis.  The Company's
products are designed to help doctors optimize treatment regimens for their
patients that lead to better outcomes and reduced costs.  The Company's
technology is also being used by numerous biopharmaceutical companies to develop
new and improved antiviral therapeutics and vaccines targeted at emerging
drug-resistant viruses.

The offer and sale of the securities being sold by ViroLogic in the private
placements will not be and has not been registered under the Securities Act of
1933, as amended, and may not be sold by ViroLogic absent registration or an
applicable exemption from registration requirements. However, the Company has
agreed to file a registration statement for the resale of the shares underlying
the preferred stock and the warrants, as well as shares issuable as dividends on
the preferred stock. This news release is not an offer to sell, or a
solicitation of an offer to buy, the securities discussed herein.

This announcement is neither an offer to sell nor a solicitation of an offer to
buy any securities of ViroLogic. Certain statements in this press release are
forward-looking, including statements relating to expected proceeds from
financing activities.  These forward-looking statements are subject to risks and
uncertainties and other factors, which may cause actual results to differ
materially from the anticipated results or other expectations expressed in such
forward-looking statements.  These risks and uncertainties include, but are not
limited to, the risk that the equity investments do not close as expected,
whether ViroLogic's products will achieve market acceptance, the timing of
pharmaceutical company clinical trials, whether payors will authorize
reimbursement for its products, whether the Company will be able to expand its
sales and marketing capabilities, whether the FDA or any other agency will
decide to regulate its products or services, whether the Company encounters
problems or delays in automating its processes, whether it successfully
introduces new products, whether others introduce competitive products, whether
intellectual property underlying its PhenoSense technology is adequate, whether
it is able to build brand loyalty and expand revenues, whether it will be able
to raise sufficient capital and other risks and uncertainties detailed from time
to time in the Company's reports to the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended December 31, 2001.

                                     # # #